Oryzon Genomics S.A. (FRA:ORN)

Market Cap	204.91M -20.2%
Revenue (ttm)	15.41M +106.2%
Net Income	-2.43M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20
Open	2.468
Previous Close	2.538
Day's Range	2.468 - 2.468
52-Week Range	2.462 - 3.490
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 28, 2026

About Oryzon Genomics

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 46
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: ORN

Financial Performance

In 2025, Oryzon Genomics's revenue was 10.93 million, an increase of 48.59% compared to the previous year's 7.36 million. Losses were -2.61 million, -27.18% less than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error